Does rTMS modulate phenotype of microglia in patients with treatment-resistant depression? A transcriptome analysis using iMG cells

• The first iMG study using the microarray analysis in patients with TRD by rTMS. • In rTMS responders, the RNA expression of 21 genes were significantly increased. • rTMS treatment may alter iMG genes including immunity in patients with TRD. Background The neuroinflammatory hypothesis has been proposed as the pathophysiology of depression, and microglia are suggested to have crucial roles by modulating neuroinflammatory responses in patients with depression. We have originally developed human blood induced microglia-like (iMG) cells, which are surrogate cells to predict activities of human brain microglia for reverse-translational research. Repetitive transcranial magnetic stimulation (rTMS) is an effective therapeutic method for improving depressive symptoms in patients with treatment-resistant depression (TRD); however, its details remain unknown. The aim of this study was to predict how rTMS alters the phenotype of microglia using iMG cells of patients with TRD. Methods Five patients with TRD were enrolled in a frequency (10 Hz) rTMS study. Microarray analysis of the iMG cells of patients with TRD at baseline and the end of the 6-week rTMS treatment was performed in the five domains of immunity, inflammation, phagocytosis, metabolic syndrome, and lipids. Results Three of the five were rTMS responders and two were non-responders for depressive symptoms. Microarray analysis of responders showed that rTMS treatment significantly increased the RNA expression of 21 genes, including genes related to neuroinflammation, acting in a direction to promote neuroinflammation, and significantly decreased four genes. Limitations The main limitations were the small sample size and the lack of control conditions using the sham rTMS procedure. Conclusion This study suggests that rTMS treatment may alter iMG genes, including immune-related genes, in patients with TRD. Future studies should confirm these findings using a larger patient sample size and a sham rTMS procedure.

Authors

Institutions

Publication Details

Journal
Journal of Affective Disorders Reports
Published
2025-04-22
DOI
https://doi.org/10.1016/j.jadr.2025.100919
Primary Topic
Neuroinflammation and Neurodegeneration Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Does rTMS modulate phenotype of microglia in patients with treatment-resistant depression? A transcriptome analysis using iMG cells

Akira Tomonari, Shogo Inamine, Akira Monji, Jun Kikuchi et al.
Journal of Affective Disorders Reports
Neuroinflammation and Neurodegeneration Mechanisms
article

Does rTMS modulate phenotype of microglia in patients with treatment-resistant depression? A transcriptome analysis using iMG cells

Akira Tomonari, Shogo Inamine, Akira Monji, Jun Kikuchi, Ken Takada, Takahiro A. Kato, Hiroshi Tateishi, Masahiro Ohgidani, Yutaka Kunitake, Shota Shiba, Yoshito Mizoguchi, Hiroko Kunitake, Toru Murakawa, Takumi Shiraishi, Masataka Hirano, Airi Fukai, Ryohei Kojima
article en

Abstract

• The first iMG study using the microarray analysis in patients with TRD by rTMS. • In rTMS responders, the RNA expression of 21 genes were significantly increased. • rTMS treatment may alter iMG genes including immunity in patients with TRD. Background The neuroinflammatory hypothesis has been proposed as the pathophysiology of depression, and microglia are suggested to have crucial roles by modulating neuroinflammatory responses in patients with depression. We have originally developed human blood induced microglia-like (iMG) cells, which are surrogate cells to predict activities of human brain microglia for reverse-translational research. Repetitive transcranial magnetic stimulation (rTMS) is an effective therapeutic method for improving depressive symptoms in patients with treatment-resistant depression (TRD); however, its details remain unknown. The aim of this study was to predict how rTMS alters the phenotype of microglia using iMG cells of patients with TRD. Methods Five patients with TRD were enrolled in a frequency (10 Hz) rTMS study. Microarray analysis of the iMG cells of patients with TRD at baseline and the end of the 6-week rTMS treatment was performed in the five domains of immunity, inflammation, phagocytosis, metabolic syndrome, and lipids. Results Three of the five were rTMS responders and two were non-responders for depressive symptoms. Microarray analysis of responders showed that rTMS treatment significantly increased the RNA expression of 21 genes, including genes related to neuroinflammation, acting in a direction to promote neuroinflammation, and significantly decreased four genes. Limitations The main limitations were the small sample size and the lack of control conditions using the sham rTMS procedure. Conclusion This study suggests that rTMS treatment may alter iMG genes, including immune-related genes, in patients with TRD. Future studies should confirm these findings using a larger patient sample size and a sham rTMS procedure.

Journal of Affective Disorders ReportsVol. 21
Kyushu University (JP), Asahikawa Medical University (JP), Saga University (JP), Hokkaido University (JP), Fukuoka Hospital (JP), SAGA Heavy Ion Medical Accelerator in Tosu (JP)
Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 89%
Neuroinflammation and Neurodegeneration Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.